Lista de obras -

A heterologous prime-boosting strategy with replicating Vaccinia virus vectors and plant-produced HIV-1 Gag/dgp41 virus-like particles

artículo científico publicado en 2017

Attenuated NYCBH vaccinia virus deleted for the E3L gene confers partial protection against lethal monkeypox virus disease in cynomolgus macaques ⬇️

artículo científico publicado el 12 de octubre de 2011

Characterization of a PKR inhibitor from the pathogenic ranavirus, Ambystoma tigrinum virus, using a heterologous vaccinia virus system

artículo científico publicado en 2017

Comparison of Immunogenicity in Rhesus Macaques of Transmitted-Founder, HIV-1 Group M Consensus, and Trivalent Mosaic Envelope Vaccines Formulated as a DNA Prime, NYVAC, and Envelope Protein Boost

artículo científico publicado en 2015

Correction for Kibler et al., "Replication-Competent NYVAC-KC Yields Improved Immunogenicity to HIV-1 Antigens in Rhesus Macaques Compared to Nonreplicating NYVAC"

scientific article published on 15 October 2019

Corrigendum to "A heterologous prime-boosting strategy with replicating Vaccinia virus vectors and plant-produced HIV-1 Gag/dgp41 virus-like particles" [Virology 507 (2017) 242-256]

scientific article published on 06 June 2019

HIV/AIDS Vaccine Candidates Based on Replication-Competent Recombinant Poxvirus NYVAC-C-KC Expressing Trimeric gp140 and Gag-Derived Virus-Like Particles or Lacking the Viral Molecule B19 That Inhibits Type I Interferon Activate Relevant HIV-1-Speci

artículo científico publicado en 2017

Immunization of Pigs by DNA Prime and Recombinant Vaccinia Virus Boost To Identify and Rank African Swine Fever Virus Immunogenic and Protective Proteins

artículo científico publicado en 2018

Immunogenicity of NYVAC prime-protein boost HIV-1 envelope vaccination and SHIV challenge of nonhuman primates

artículo científico publicado en 2018

Improved NYVAC-based vaccine vectors

artículo científico publicado en 2011

Improved innate and adaptive immunostimulation by genetically modified HIV-1 protein expressing NYVAC vectors

artículo científico publicado en 2011

In Vitro Characterization of a Nineteenth-Century Therapy for Smallpox ⬇️

artículo científico publicado el 9 de marzo de 2012

Inhibition of DAI-dependent necroptosis by the Z-DNA binding domain of the vaccinia virus innate immune evasion protein, E3.

artículo científico publicado en 2017

Inhibition of PKR by RNA and DNA viruses

artículo científico publicado en 2006

Inhibition of PKR by vaccinia virus: role of the N- and C-terminal domains of E3L.

artículo científico publicado en 2004

Innate Immune Evasion Mediated by the Ambystoma tigrinum Virus Eukaryotic Translation Initiation Factor 2α Homologue ⬇️

artículo científico publicado el 9 de marzo de 2011

Interaction between unrelated viruses during in vivo co-infection to limit pathology and immunity

artículo científico publicado en 2015

Mouse hepatitis coronavirus A59 nucleocapsid protein is a type I interferon antagonist

artículo científico publicado en 2006

Potential To Streamline Heterologous DNA Prime and NYVAC/Protein Boost HIV Vaccine Regimens in Rhesus Macaques by Employing Improved Antigens

artículo científico publicado en 2016

Poxvirus vector-based HIV vaccines

artículo científico publicado en 2010

Priming with a potent HIV-1 DNA vaccine frames the quality of immune responses prior to a poxvirus and protein boost

article

Proceedings of the Frontiers of Retrovirology Conference 2016.

artículo científico publicado en 2016

Protein kinase PKR-dependent activation of mitogen-activated protein kinases occurs through mitochondrial adapter IPS-1 and is antagonized by vaccinia virus E3L.

artículo científico publicado en 2009

Regulation of inflammatory gene expression in PBMCs by immunostimulatory botanicals

artículo científico publicado en 2010

Replication-competent NYVAC-KC yields improved immunogenicity to HIV-1 antigens in rhesus macaques, compared to non-replicating NYVAC

article

Superiority in Rhesus Macaques of Targeting HIV-1 Env gp140 to CD40 versus LOX-1 in Combination with Replication-Competent NYVAC-KC for Induction of Env-Specific Antibody and T Cell Responses

artículo científico publicado en 2017

Synthetic long peptide booster immunization in rhesus macaques primed with replication-competent NYVAC-C-KC induces a balanced CD4/CD8 T-cell and antibody response against the conserved regions of HIV-1.

artículo científico publicado en 2015

Targeting HIV-1 Env gp140 to LOX-1 Elicits Immune Responses in Rhesus Macaques

artículo científico publicado en 2016

The N-terminal domain of the vaccinia virus E3L-protein is required for neurovirulence, but not induction of a protective immune response

artículo científico publicado en 2005

The NYCBH vaccinia virus deleted for the innate immune evasion gene, E3L, protects rabbits against lethal challenge by rabbitpox virus

artículo científico publicado en 2011

The attenuated NYCBH vaccinia virus deleted for the immune evasion gene, E3L, completely protects mice against heterologous challenge with ectromelia virus ⬇️

artículo científico publicado el 5 de octubre de 2011

The role of the PKR-inhibitory genes, E3L and K3L, in determining vaccinia virus host range

artículo científico publicado en 2002

Use of a negative selectable marker for rapid selection of recombinant vaccinia virus ⬇️

artículo científico publicado el 1 de mayo de 2011

Use of a recombinant vaccinia virus expressing interferon gamma for post-exposure protection against vaccinia and ectromelia viruses

artículo científico publicado en 2013

Vaccinia virus vaccines: past, present and future

artículo científico publicado en 2009

Vaccinia viruses with mutations in the E3L gene as potential replication-competent, attenuated vaccines: scarification vaccination

artículo científico publicado en 2008

Virological and immunological characterization of novel NYVAC-based HIV/AIDS vaccine candidates expressing clade C trimeric soluble gp140(ZM96) and Gag(ZM96)-Pol-Nef(CN54) as virus-like particles.

artículo científico publicado en 2014

Lista de obras de

A heterologous prime-boosting strategy with replicating Vaccinia virus vectors and plant-produced HIV-1 Gag/dgp41 virus-like particles

Attenuated NYCBH vaccinia virus deleted for the E3L gene confers partial protection against lethal monkeypox virus disease in cynomolgus macaques ⬇️

Characterization of a PKR inhibitor from the pathogenic ranavirus, Ambystoma tigrinum virus, using a heterologous vaccinia virus system

Comparison of Immunogenicity in Rhesus Macaques of Transmitted-Founder, HIV-1 Group M Consensus, and Trivalent Mosaic Envelope Vaccines Formulated as a DNA Prime, NYVAC, and Envelope Protein Boost

Correction for Kibler et al., "Replication-Competent NYVAC-KC Yields Improved Immunogenicity to HIV-1 Antigens in Rhesus Macaques Compared to Nonreplicating NYVAC"

Corrigendum to "A heterologous prime-boosting strategy with replicating Vaccinia virus vectors and plant-produced HIV-1 Gag/dgp41 virus-like particles" [Virology 507 (2017) 242-256]

HIV/AIDS Vaccine Candidates Based on Replication-Competent Recombinant Poxvirus NYVAC-C-KC Expressing Trimeric gp140 and Gag-Derived Virus-Like Particles or Lacking the Viral Molecule B19 That Inhibits Type I Interferon Activate Relevant HIV-1-Speci

Immunization of Pigs by DNA Prime and Recombinant Vaccinia Virus Boost To Identify and Rank African Swine Fever Virus Immunogenic and Protective Proteins

Immunogenicity of NYVAC prime-protein boost HIV-1 envelope vaccination and SHIV challenge of nonhuman primates

Improved NYVAC-based vaccine vectors

Improved innate and adaptive immunostimulation by genetically modified HIV-1 protein expressing NYVAC vectors

In Vitro Characterization of a Nineteenth-Century Therapy for Smallpox ⬇️

Inhibition of DAI-dependent necroptosis by the Z-DNA binding domain of the vaccinia virus innate immune evasion protein, E3.

Inhibition of PKR by RNA and DNA viruses

Inhibition of PKR by vaccinia virus: role of the N- and C-terminal domains of E3L.

Innate Immune Evasion Mediated by the Ambystoma tigrinum Virus Eukaryotic Translation Initiation Factor 2α Homologue ⬇️

Interaction between unrelated viruses during in vivo co-infection to limit pathology and immunity

Mouse hepatitis coronavirus A59 nucleocapsid protein is a type I interferon antagonist

Potential To Streamline Heterologous DNA Prime and NYVAC/Protein Boost HIV Vaccine Regimens in Rhesus Macaques by Employing Improved Antigens

Poxvirus vector-based HIV vaccines

Priming with a potent HIV-1 DNA vaccine frames the quality of immune responses prior to a poxvirus and protein boost

Proceedings of the Frontiers of Retrovirology Conference 2016.

Protein kinase PKR-dependent activation of mitogen-activated protein kinases occurs through mitochondrial adapter IPS-1 and is antagonized by vaccinia virus E3L.

Regulation of inflammatory gene expression in PBMCs by immunostimulatory botanicals

Replication-competent NYVAC-KC yields improved immunogenicity to HIV-1 antigens in rhesus macaques, compared to non-replicating NYVAC

Superiority in Rhesus Macaques of Targeting HIV-1 Env gp140 to CD40 versus LOX-1 in Combination with Replication-Competent NYVAC-KC for Induction of Env-Specific Antibody and T Cell Responses

Synthetic long peptide booster immunization in rhesus macaques primed with replication-competent NYVAC-C-KC induces a balanced CD4/CD8 T-cell and antibody response against the conserved regions of HIV-1.

Targeting HIV-1 Env gp140 to LOX-1 Elicits Immune Responses in Rhesus Macaques

The N-terminal domain of the vaccinia virus E3L-protein is required for neurovirulence, but not induction of a protective immune response

The NYCBH vaccinia virus deleted for the innate immune evasion gene, E3L, protects rabbits against lethal challenge by rabbitpox virus

The attenuated NYCBH vaccinia virus deleted for the immune evasion gene, E3L, completely protects mice against heterologous challenge with ectromelia virus ⬇️

The role of the PKR-inhibitory genes, E3L and K3L, in determining vaccinia virus host range

Use of a negative selectable marker for rapid selection of recombinant vaccinia virus ⬇️

Use of a recombinant vaccinia virus expressing interferon gamma for post-exposure protection against vaccinia and ectromelia viruses

Vaccinia virus vaccines: past, present and future

Vaccinia viruses with mutations in the E3L gene as potential replication-competent, attenuated vaccines: scarification vaccination

Virological and immunological characterization of novel NYVAC-based HIV/AIDS vaccine candidates expressing clade C trimeric soluble gp140(ZM96) and Gag(ZM96)-Pol-Nef(CN54) as virus-like particles.